Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-01 in first-line KRAS G12C-mutant advanced NSCLC
jRCT2061230080Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of olomorasib in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with treatment-emergent adverse events and Progression-free survival. Started Feb 2024; status: recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061230080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230080.